# 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab

> **NCT00600340** · PHASE3 · COMPLETED · sponsor: **Central European Cooperative Oncology Group** · enrollment: 564 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **BIOLOGICAL:** Bevacizumab and Paclitaxel
- **BIOLOGICAL:** Bevacizumab and Capecitabine

## Key facts

- **NCT ID:** NCT00600340
- **Lead sponsor:** Central European Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 564 (ACTUAL)
- **Last updated:** 2019-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600340, "2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00600340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*